metastasis and recurrence rates. In addition, video-assisted thoracoscopic surgery (VATS) as a less invasive surgical method is widely used for clinical stage I NSCLC during lobectomy, segmentectomy, and wedge resection. Lobectomy is a traditionally gold standard for early stage NSCLC treatment. In recent years, segmentectomy and wedge resection as alternative sublobar resection to lobectomy are recommended. Many studies have indicated that sublobar resection results in equivalent outcomes in patients with stage I NSCLC in comparison with lobectomy, and it is gradually considered that pneumonectomy is unnecessary. However, sublobar resection for NSCLC treatment remains controversial due to an increased risk in local recurrence and poorer long-term survival compared to lobectomy, thus additional local therapy is recommended to patients undergoing sublobar resection. Method: Eligible studies were retrieved from PubMed, Embase, and Cochrane Library. The 1, 2 or 5-year overall survival (OS) and disease-free survival (DFS), and complications rates were used as outcomes indictors. The pooled results for comparison indicators were measured by odds ratios (ORs) with 95% confidence interval (CI) as dichotomous variables. The random effects model was used for all test models in the present study. The consistency assessment in this network meta-analysis was conducted by Node-splitting analysis. Result: A total of 23 studies encompassing 13406 early stage NSCLC patients were included into this network meta-analysis. The results revealed that although 1, 2 and 5-year OS and DFS of lobetomy was superior to segmentectomy and wedge resection, and segmentectomy was better than wedge resection, except for 2-year OS, only result of 5-years OS between groups (wedge resection vs. segmentectomy, OR¼ 0.56, 95%CI: 0.36-0.87; wedge resection vs. lobetomy, OR¼ 0.51, 95%CI: 0.33-0.79) were significant difference. On the contrary, the complications rate in wedge resection was significant lower than that of lobetomy (lobetomy vs. wedge resection, OR¼ 1.73, 95%CI: 1.05-2.72) and segmentectomy (segmentectomy vs. wedge resection, OR¼ 1.66, 95%CI: 1.02-2.74), and it was highest in lobetomy. Conclusion: Segmentectomy might be recommended as a reasonable alternative to lobectomy with lower complications rate for early stage NSCLC treatment.
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P3.01-60 A Novel MET D1246H Mutation After Progression of EGFR-TKI/MET Inhibitor Combined Therapy in a NSCLC Patient with Acquired MET Amplification
Y. Liang, 1 Q. Chen, 2 Y. Lin, 3 H. Liu, 4 B. Qiu 4 1 Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/CN, 2 Sun Yat-Sen University School of Medicine, Guangzhou/CN, 3 Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou/CN, 4 Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou/CN Background: MET amplification was the second common acquired resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC). It may be benefited by combinations of EGFR TKIs and the MET inhibitor. However, the acquired resistance mechanism to this combination therapy remains to be identified. Method: A patient with advanced lung adenocarcinoma harboring both EGFR L858R mutation and acquired MET amplification, progressed after the combination of MET inhibitor gefitinib and EGFR-TKI crizotinib. The next generation sequencing (NGS) based circulating tumor DNA (ctDNA) assay was performed. Results were applied to discover a novel mutation after resistance to target therapy. Result: A 52-year-old Chinese never-smoking woman with EGFR L858R mutant adenocarcinoma had systemic progression after gefitinib, pemetrexed/platinum-pemetrexed maintenance, and SBRT local progressed lung metastasis. The NGSbased ctDNA analysis revealed that the MET amplification was found besides continually present EGFR L858R mutation. The patient started treatment with crizotinib (250mg Bid) and gefitinib (250mg/d). The NGS was performed after progression of this combined therapy. It revealed two novel mutations of MET D1246H (MAF 0.9%) and EGFR T790M mutation (MAF 0.2%), in addition to the initial presence of EGFR L858R mutation (MAF 9.8%) and MET amplification (LR 6.7). The patient started to receive osimertinib (80mg/d) and cabozantinib (20mg/d and later increased to 40mg/d). The patient tolerated this combination well while the symptoms did not relief. After 8 weeks, the re-scan CT showed pulmonary lesions progressed. The NGS-based ctDNA assay performed again and it showed that L858R mutation (MAF 11.4%) and MET amplification (LR 4.9) presented while the EGFR T790 mutation and MET D1246H disappeared. Then the patient received osimertinib (80mg/d) and crizotinib (250mg Bid). The patient felt symptoms improved greatly after 1 week's administration and CT scan after 2 months showed good response. However, one more month later, the patient felt deteriorative symptoms of dyspnea and chest X-ray showed increasing pleural effusion, progressing pulmonary lesions. The NGS-based ctDNA assay at that time revealed that MET D1246H (MAF 14.4%) appeared again, in addition to the initial presence of EGFR L858R mutation (MAF 22.4%) and MET amplification (LR 8.2) while the EGFR T790 mutation was not existed. However, the patient died because of respiratory failure. Conclusion: MET mutations might be a potential acquired resistance mechanism after progression during EGFR-TKI /MET inhibitor combined therapy in advanced NSCLC patient with primary EGFR mutation and secondary acquired MET amplification. Keywords: non-small cell lung cancer, Met mutation, acquired resistance mechanism P3.01-61 EGFR and KRAS Mutational Status and Significance in Greek Patients with Advanced Non Small Cell Lung Cancer Background: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC); their prognostic role in advanced NSCLC is still under dispute. Given that ethnicity may play a role on mutational profiles of NSCLC, we report here on KRAS mutations in Greek NSCLC patients. Method: KRAS and EGFR genotypes were evaluated in 424 NSCLC patients diagnosed from March 2000 to December 2012 and associated with clinicopathological parameters. Outcome comparisons were performed in 234 metastatic patients with available treatment data, following 1st line chemotherapy without tyrosine kinase inhibitors. Result: KRAS mutations were found in 71 tumors of all histologies (22.2% in adenocarcinomas); most common types were p.G12C (39.5%), p.G12D (32%) and p.G12V (14%). EGFR mutations were found in 45 tumors (14.8% in adenocarcinomas; 72.6% of the classical type) and were mutually exclusive with KRAS mutations except for one case. At a median 3-year follow-up for all patients, KRAS status was a strong negative prognostic factor for overall survival (OS, p¼0.0213) but not for progression-free survival (PFS), irrespective of mutation type. KRAS mutations conferred 64% increased risk of death in all 1st line treated patients and the worst OS compared to EGFR and any wild-type status in 1st line platinum-treated patients (p¼0.0547). Rare EGFR mutations conferred significantly better outcome to platinum-treated patients (OS, p¼0.0074; PFS, p¼0.0338). Conclusion: The presence of KRAS mutations seemed of adverse prognostic significance for survival, also in the presence of platinum-based 1st line treatment, while no prognostic differences were seen among different types of mutations. Keywords: KRAS, EGFR, NSCLC
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